Tysabri review launched in Europe
Posted: Mon May 11, 2015 1:30 am
In light of growing evidence, the European Medicines Agency (EMA) has been asked to launch a review of the multiple sclerosis drug Tysabri to assess whether advice on managing known risks for progressive multifocal leukoencephalopathy (PML) should be revised.... Read More - http://www.ms-uk.org/tysabri